sur VALBIOTIS (EPA:ALVAL)
Valbiotis strengthens its financing to support its commercial expansion
Valbiotis, a laboratory specializing in cardiometabolic health, announces new financing to support its commercial growth. On November 16, 2026, the company secured €1.65 million in non-dilutive bank loans from its long-standing partners, Société Générale and BNP Paribas, as well as from Bpifrance. A factoring agreement was also signed with BNP Paribas Factor, with an authorized credit limit of €500,000, to manage working capital requirements related to accounts receivable.
The financing secured strengthens Valbiotis' financial flexibility without diluting its shareholding. As of June 30, 2026, the company already had €11.7 million in cash, guaranteeing its financing until the end of 2027. Sébastien Peltier, Chairman of the Board, emphasizes that these funds will allow Valbiotis to effectively support the anticipated increase in pharmacy sales.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de VALBIOTIS